Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Biological: bevacizumab
Drug: erlotinib hydrochloride
Genetic: fluorescence in situ hybridization
Genetic: gene expression analysis
Other: immunologic technique
Other: laboratory biomarker analysis
Procedure: biopsy

Registration Number: NCT00466687

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Brief Summary: RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IV melanoma.

Detailed Description: OBJECTIVES:

Primary

* Determine the overall response rate, response duration, and frequency of progression-free survival at 6 months in patients with stage IV melanoma treated with erlotinib hydrochloride and bevacizumab.

* Determine objective responses in patients treated with this regimen.

Secondary

* Determine the overall safety and tolerability of this regimen in these patients.

* Evaluate tissue blocks for EGFR by monoclonal antibody H11 (DAKO) or fluorescence in situ hybridization(FISH)7p12-specific probe-overexpression or amplification in patients treated with this regimen.

OUTLINE: This is a multicenter study.

Patients receive oral erlotinib hydrochloride once daily on days 1-28 and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo tissue collection to analyze EGFR by monoclonal antibody H11 (DAKO) or fluorescence in situ hybridization (FISH) 7p12-specific probe-overexpression or amplification. Biological markers AKT, MAPK, p27, p21, CD13, CD34, and factor VIII are also measured.

After completion of study treatment, patients are followed periodically.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 34

Inclusion Criteria

Measurable Stage IV melanoma
Easter Cooperative Oncology Group (ECOG) Performance Status must be 0-1
Good organ function as demonstrated by, Creatinine <2.mg/dl, AST or ALT <5 times upper limit of normal for subjects with documented liver metastases; <2.5 times the upper limit of normal (ULN) for subjects without evidence of liver metastases, bilirubin<2.0mg/dl,, absolute neutrophil count (ANC)>1500/ul, platelets>75k/ul, hemoglobin (Hgb)>9 (may be transfused to obtain)
Prior therapy: adjuvant interferon (IFN) allowed; no more than one prior regimen for advanced stage IV disease
Patients must have a life expectancy of >3 months
Patients with brain metastases are eligible only if they fulfill the following: resected or stereotactic treatment a minimum of 3 months previously and no active CNS disease since then; brain metastases treated greater than 6 months ago without evidence of progression or hemorrhage, <1cm in size per lesion (up to 3 lesions), and off all steroids
Patients may not have received other agents, either investigational or marketed, which act by either EGFr inhibition or anti-angiogenesis mechanisms. Other epidermal growth factor receptor (EGFR) inhibitors include (but are not limited to): Iressa, erbitux, CI-1033. Angiogenesis inhibitors include (but are not limited to): SU5416, SU6668, SU 0122348, CP547632, VEGF Trap, anti-integrin αVβ3.
Recovered from toxicity of major surgery (4 wks), chemotherapy or biologic therapy (4 wks), and/or radiation therapy (2 wks)
No active other malignancy within 12 months
No active systemic infection
Over age of 18 years and signed IRB approved informed consent

Exclusion Criteria

Subjects meeting any of the following criteria (3.2.2-3.2.16) are ineligible for study entry
Compromised renal or hepatic function as defined by Creatinine >2.0mg/dl, aspartate transaminase (AST) or alanine transaminase (ALT) >5 times upper limit of normal for subjects with documented liver metastases; >2.5 times the upper limit of normal (ULN) for subjects without evidence of liver metastases
Patient may not be part of any other investigational studies
internationalized normal ratio (INR) > 1.5
Patients with PEG or G-tube are ineligible.
Major surgical procedure, open biopsy; or significant traumatic injury within 28 days, or anticipation of need for major surgical procedure during the course of the study
Any non-healing wound, ulcer, or bone fracture.
Any clinical evidence or history of a bleeding diathesis or coagulopathy.
Patients with a history of deep vein thrombosis or thromboembolic disease within the past 6 months.
History of acute myocardial infarction within 6 months. In addition, patients are ineligible if they have clinically significant cardiovascular disease ((e.g., uncontrolled hypertension [blood pressure of >160/110 mmHg on medication], New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac dysrhythmia requiring medication, or peripheral vascular disease (Grade II or greater)
Patients with > 1+ proteinuria will have 24-hour urine collection; for protein. Patients with ≥ 1gm protein/24 hrs will be excluded
If child bearing age must not be pregnant or nursing and use methods to prevent pregnancy
History or evidence upon physical examination of central nervous system (CNS) disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, or history of stroke)
Inability to comply with study and/or follow-up procedures
History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk from treatment complications.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Therapeutic Intervention	erlotinib hydrochloride	Tarceva and Avastin: * Tarceva: 150mg PO, days 1-28 * Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course
Therapeutic Intervention	bevacizumab	Tarceva and Avastin: * Tarceva: 150mg PO, days 1-28 * Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course
Therapeutic Intervention	fluorescence in situ hybridization	Tarceva and Avastin: * Tarceva: 150mg PO, days 1-28 * Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course
Therapeutic Intervention	gene expression analysis	Tarceva and Avastin: * Tarceva: 150mg PO, days 1-28 * Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course
Therapeutic Intervention	immunologic technique	Tarceva and Avastin: * Tarceva: 150mg PO, days 1-28 * Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course
Therapeutic Intervention	laboratory biomarker analysis	Tarceva and Avastin: * Tarceva: 150mg PO, days 1-28 * Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course
Therapeutic Intervention	biopsy	Tarceva and Avastin: * Tarceva: 150mg PO, days 1-28 * Avastin: 10mg/kg, IV infusion, days 1,15 Regimen will be repeated every 28 days = 1 course

Primary Outcome Measures

Name	Time	Method
Number of Patients With Response	At 6 months	Per Response Evaluation Criteria in Solid Tumor (RECIST): Progressive disease (PD): \>=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): \>=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD.

Secondary Outcome Measures

Name	Time	Method
Time to Disease Progression.	up to one year after off-study date	Time from on study date to date of progression in months, if the progression happened in the patient. Disease progression is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions with reference to the smallest sum LD since treatment began or the appearance of one or more new lesions.
Progression-free Survival at 6 Months	6 months	Patients with Progression-free survival at 6 months
Number of Patients With Each Worst-grade Toxicity Response	Day 1 of each 28-day cycle for 6 cycles (168 days)	Number of patients with worst-grade toxicity at each of five grades following National Cancer Institute Common Toxicity Criteria with grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life-threatening/disabling, 5 = death.

Trial Locations

Locations (4): Vanderbilt-Ingram Cancer Center
🇺🇸
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center - Cool Springs
🇺🇸
Nashville, Tennessee, United States
Sarah Cannon Research Institute
🇺🇸
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center at Franklin
🇺🇸
Nashville, Tennessee, United States